Nuvation Bio Inc.
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
NUVB$4.35+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share data)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $125,391 | $164,086 |
| Accounts receivable, net of allowance for credit loss of $nil and $nil | 22,723 | 16,076 |
| Inventory | 15,844 | 11,411 |
| Prepaid expenses and other current assets | 15,972 | 11,536 |
| Marketable securities | 408,338 | 365,125 |
| Interest receivable on marketable securities | 3,261 | 3,285 |
| Total current assets | 591,529 | 571,519 |
| Property and equipment, net of accumulated depreciation of $1,260 and $1,184, respectively | 535 | 564 |
| Intangible assets, net of accumulated amortization of $2,315 and $1,856, respectively | 10,755 | 11,214 |
| Operating lease right-of-use assets | 3,598 | 3,918 |
| Other non-current assets | 3,824 | 7,607 |
| Total assets | $610,241 | $594,822 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $22,435 | $9,479 |
| Current operating lease liabilities | 1,838 | 1,880 |
| Contract liabilities, current portion | 8,651 | 7,515 |
| Liability related to revenue interest financing agreement, current portion | 7,944 | 9,585 |
| Short-term borrowings | 5,790 | 5,724 |
| Warrant liability | — | 2,865 |
| Accrued expenses | 32,864 | 45,183 |
| Total current liabilities | 79,522 | 82,231 |
| Contract liabilities, net of current portion | 9,743 | 11,305 |
| Non-current operating lease liabilities | 2,199 | 2,543 |
| Non-current liability related to revenue interest financing agreement, net of deferred financing costs of $4,030 and $4,241, respectively | 151,886 | 145,819 |
| Long-term borrowings, net of deferred financing costs of $2,923 and $3,042, respectively | 47,327 | 47,208 |
| Total liabilities | 290,677 | 289,106 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity | ||
| Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000, Class B 60,000,000) shares authorized as of March 31, 2026 and December 31, 2025 respectively, 347,693,331 (Class A 346,693,331, Class B 1,000,000) and 346,503,675 (Class A 345,503,675, Class B 1,000,000) shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 1,431,214 | 1,421,273 |
| Accumulated deficit | (1,109,973) | (1,115,370) |
| Accumulated other comprehensive income | (1,677) | (187) |
| Total stockholders’ equity | 319,564 | 305,716 |
| Total liabilities and stockholders’ equity | $610,241 | $594,822 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.